1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

Ildong Begins R&D Transformation With 'Quick Win, Fast Fail' Strategy

Role For Internal/External Collaborations

 
• By Jung Won Shin

South Korea’s Ildong Pharmaceutical has begun a major transformation from an OTC-focused firm to an innovative R&D-based operation that aims to compete with global big pharma rivals, helped by both internal and external alliances, its R&D head says in an interview with Scrip.

Ildong Pharm headquarters
Ildong Shifts Focus To Innovative R&D From OTCs • Source: Ildong Pharmaceutical

With a recently acquired clinical pharmacology firm and new drug development affiliate under its wing, Ildong Pharmaceutical Co., Ltd. is aiming to transform into an innovative R&D-based operation that can truly compete shoulder-to-shoulder with global big pharma companies.

“As Gilead Sciences, Inc. has grown into a high-ranking global big pharma from a small biotech within a short period of time, this is the direction Ildong wants to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Korea State R&D Fund Seeks Continuity To Enable Seamless Support

 
• By Jung Won Shin

The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.

More from Focus On Asia